Cargando…
Very Late Pathological Responses to Cobalt–Chromium Everolimus‐Eluting, Stainless Steel Sirolimus‐Eluting, and Cobalt–Chromium Bare Metal Stents in Humans
BACKGROUND: The “very late” clinical outcomes for durable polymer drug‐eluting stents and bare metal stents (BMSs) have been shown to be dissimilar in clinical studies. Conceptually, the long‐term vascular compatibility of BMSs is still regarded to be superior to drug‐eluting stents; however, no pat...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721792/ https://www.ncbi.nlm.nih.gov/pubmed/29150493 http://dx.doi.org/10.1161/JAHA.117.007244 |
_version_ | 1783284882738249728 |
---|---|
author | Mori, Hiroyoshi Atmakuri, Dheeraj R. Torii, Sho Braumann, Ryan Smith, Samantha Jinnouchi, Hiroyuki Gupta, Anuj Harari, Emanuel Shkullaku, Melsi Kutys, Robert Fowler, David Romero, Maria Virmani, Renu Finn, Aloke V. |
author_facet | Mori, Hiroyoshi Atmakuri, Dheeraj R. Torii, Sho Braumann, Ryan Smith, Samantha Jinnouchi, Hiroyuki Gupta, Anuj Harari, Emanuel Shkullaku, Melsi Kutys, Robert Fowler, David Romero, Maria Virmani, Renu Finn, Aloke V. |
author_sort | Mori, Hiroyoshi |
collection | PubMed |
description | BACKGROUND: The “very late” clinical outcomes for durable polymer drug‐eluting stents and bare metal stents (BMSs) have been shown to be dissimilar in clinical studies. Conceptually, the long‐term vascular compatibility of BMSs is still regarded to be superior to drug‐eluting stents; however, no pathologic study to date has specifically addressed this issue. We evaluated the very late (≥1 year) pathologic responses to durable polymer drug‐eluting stents (cobalt–chromium [CoCr] everolimus‐eluting stents [EESs] and stainless steel sirolimus‐eluting stents [SS‐SESs]) versus BMSs (CoCr‐BMSs). METHODS AND RESULTS: From the CVPath stent registry, we studied a total of 119 lesions (40 CoCr‐EESs, 44 SS‐SESs, 35 CoCr‐BMSs) from 92 autopsy cases with a duration ranging from 1 to 5 years. Sections of stented coronary segments were pathologically analyzed. Inflammation score and the percentage of struts with giant cells were lowest in CoCr‐EESs (median inflammation score: 0.6; median percentage of struts with giant cells: 3.8%) followed by CoCr‐BMSs (median inflammation score: 1.3 [P<0.01]; median percentage of struts with giant cells: 8.9% [P=0.02]) and SS‐SESs (median inflammation score: 1.7 [P<0.01]; median percentage of struts with giant cells: 15.3% [P<0.01]). Polymer delamination was observed exclusively in SS‐SESs and was associated with increased inflammatory and giant cell reactions. The prevalence of neoatherosclerosis with CoCr‐EESs (50%) was significantly less than with SS‐SESs (77%, P=0.02) but significantly greater than with CoCr‐BMSs (20%, P<0.01). CONCLUSIONS: CoCr‐EESs, SS‐SESs, and BMSs each demonstrated distinct vascular responses. CoCr‐EESs demonstrated the least inflammation, near‐equivalent healing to BMSs, and lower neointimal formation. These results challenge the belief that BMSs have superior biocompatibility compared with some polymeric coated drug‐eluting stents and may have implications for future stent design. |
format | Online Article Text |
id | pubmed-5721792 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-57217922017-12-12 Very Late Pathological Responses to Cobalt–Chromium Everolimus‐Eluting, Stainless Steel Sirolimus‐Eluting, and Cobalt–Chromium Bare Metal Stents in Humans Mori, Hiroyoshi Atmakuri, Dheeraj R. Torii, Sho Braumann, Ryan Smith, Samantha Jinnouchi, Hiroyuki Gupta, Anuj Harari, Emanuel Shkullaku, Melsi Kutys, Robert Fowler, David Romero, Maria Virmani, Renu Finn, Aloke V. J Am Heart Assoc Original Research BACKGROUND: The “very late” clinical outcomes for durable polymer drug‐eluting stents and bare metal stents (BMSs) have been shown to be dissimilar in clinical studies. Conceptually, the long‐term vascular compatibility of BMSs is still regarded to be superior to drug‐eluting stents; however, no pathologic study to date has specifically addressed this issue. We evaluated the very late (≥1 year) pathologic responses to durable polymer drug‐eluting stents (cobalt–chromium [CoCr] everolimus‐eluting stents [EESs] and stainless steel sirolimus‐eluting stents [SS‐SESs]) versus BMSs (CoCr‐BMSs). METHODS AND RESULTS: From the CVPath stent registry, we studied a total of 119 lesions (40 CoCr‐EESs, 44 SS‐SESs, 35 CoCr‐BMSs) from 92 autopsy cases with a duration ranging from 1 to 5 years. Sections of stented coronary segments were pathologically analyzed. Inflammation score and the percentage of struts with giant cells were lowest in CoCr‐EESs (median inflammation score: 0.6; median percentage of struts with giant cells: 3.8%) followed by CoCr‐BMSs (median inflammation score: 1.3 [P<0.01]; median percentage of struts with giant cells: 8.9% [P=0.02]) and SS‐SESs (median inflammation score: 1.7 [P<0.01]; median percentage of struts with giant cells: 15.3% [P<0.01]). Polymer delamination was observed exclusively in SS‐SESs and was associated with increased inflammatory and giant cell reactions. The prevalence of neoatherosclerosis with CoCr‐EESs (50%) was significantly less than with SS‐SESs (77%, P=0.02) but significantly greater than with CoCr‐BMSs (20%, P<0.01). CONCLUSIONS: CoCr‐EESs, SS‐SESs, and BMSs each demonstrated distinct vascular responses. CoCr‐EESs demonstrated the least inflammation, near‐equivalent healing to BMSs, and lower neointimal formation. These results challenge the belief that BMSs have superior biocompatibility compared with some polymeric coated drug‐eluting stents and may have implications for future stent design. John Wiley and Sons Inc. 2017-11-17 /pmc/articles/PMC5721792/ /pubmed/29150493 http://dx.doi.org/10.1161/JAHA.117.007244 Text en © 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Research Mori, Hiroyoshi Atmakuri, Dheeraj R. Torii, Sho Braumann, Ryan Smith, Samantha Jinnouchi, Hiroyuki Gupta, Anuj Harari, Emanuel Shkullaku, Melsi Kutys, Robert Fowler, David Romero, Maria Virmani, Renu Finn, Aloke V. Very Late Pathological Responses to Cobalt–Chromium Everolimus‐Eluting, Stainless Steel Sirolimus‐Eluting, and Cobalt–Chromium Bare Metal Stents in Humans |
title | Very Late Pathological Responses to Cobalt–Chromium Everolimus‐Eluting, Stainless Steel Sirolimus‐Eluting, and Cobalt–Chromium Bare Metal Stents in Humans |
title_full | Very Late Pathological Responses to Cobalt–Chromium Everolimus‐Eluting, Stainless Steel Sirolimus‐Eluting, and Cobalt–Chromium Bare Metal Stents in Humans |
title_fullStr | Very Late Pathological Responses to Cobalt–Chromium Everolimus‐Eluting, Stainless Steel Sirolimus‐Eluting, and Cobalt–Chromium Bare Metal Stents in Humans |
title_full_unstemmed | Very Late Pathological Responses to Cobalt–Chromium Everolimus‐Eluting, Stainless Steel Sirolimus‐Eluting, and Cobalt–Chromium Bare Metal Stents in Humans |
title_short | Very Late Pathological Responses to Cobalt–Chromium Everolimus‐Eluting, Stainless Steel Sirolimus‐Eluting, and Cobalt–Chromium Bare Metal Stents in Humans |
title_sort | very late pathological responses to cobalt–chromium everolimus‐eluting, stainless steel sirolimus‐eluting, and cobalt–chromium bare metal stents in humans |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721792/ https://www.ncbi.nlm.nih.gov/pubmed/29150493 http://dx.doi.org/10.1161/JAHA.117.007244 |
work_keys_str_mv | AT morihiroyoshi verylatepathologicalresponsestocobaltchromiumeverolimuselutingstainlesssteelsirolimuselutingandcobaltchromiumbaremetalstentsinhumans AT atmakuridheerajr verylatepathologicalresponsestocobaltchromiumeverolimuselutingstainlesssteelsirolimuselutingandcobaltchromiumbaremetalstentsinhumans AT toriisho verylatepathologicalresponsestocobaltchromiumeverolimuselutingstainlesssteelsirolimuselutingandcobaltchromiumbaremetalstentsinhumans AT braumannryan verylatepathologicalresponsestocobaltchromiumeverolimuselutingstainlesssteelsirolimuselutingandcobaltchromiumbaremetalstentsinhumans AT smithsamantha verylatepathologicalresponsestocobaltchromiumeverolimuselutingstainlesssteelsirolimuselutingandcobaltchromiumbaremetalstentsinhumans AT jinnouchihiroyuki verylatepathologicalresponsestocobaltchromiumeverolimuselutingstainlesssteelsirolimuselutingandcobaltchromiumbaremetalstentsinhumans AT guptaanuj verylatepathologicalresponsestocobaltchromiumeverolimuselutingstainlesssteelsirolimuselutingandcobaltchromiumbaremetalstentsinhumans AT harariemanuel verylatepathologicalresponsestocobaltchromiumeverolimuselutingstainlesssteelsirolimuselutingandcobaltchromiumbaremetalstentsinhumans AT shkullakumelsi verylatepathologicalresponsestocobaltchromiumeverolimuselutingstainlesssteelsirolimuselutingandcobaltchromiumbaremetalstentsinhumans AT kutysrobert verylatepathologicalresponsestocobaltchromiumeverolimuselutingstainlesssteelsirolimuselutingandcobaltchromiumbaremetalstentsinhumans AT fowlerdavid verylatepathologicalresponsestocobaltchromiumeverolimuselutingstainlesssteelsirolimuselutingandcobaltchromiumbaremetalstentsinhumans AT romeromaria verylatepathologicalresponsestocobaltchromiumeverolimuselutingstainlesssteelsirolimuselutingandcobaltchromiumbaremetalstentsinhumans AT virmanirenu verylatepathologicalresponsestocobaltchromiumeverolimuselutingstainlesssteelsirolimuselutingandcobaltchromiumbaremetalstentsinhumans AT finnalokev verylatepathologicalresponsestocobaltchromiumeverolimuselutingstainlesssteelsirolimuselutingandcobaltchromiumbaremetalstentsinhumans |